Weight loss jab shows promise for rare obesity syndrome
NCT ID NCT07602803
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective weekly weight loss injections (like Mounjaro) are for adults with Bardet-Biedl Syndrome (BBS), a rare genetic condition that often causes severe obesity. Researchers compared weight changes in 300 patients who took the medication versus those who did not. The goal was to see if these injections can help manage weight long-term in people with BBS.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BARDED-BIEDL SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Queen Elizabeth Hospital Birmingham
Birmingham, West Midlands, B15 2GW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a drug that targets the brain's hunger pathway help people with Bardet-Biedl syndrome?
- New registry aims to unlock secrets of rare Kidney-Liver diseases
- Thousands join fight against blindness by sharing their stories
- Scientists hunt for early warning signs of kidney failure in rare genetic diseases
- Genetic clues to childhood obesity: study seeks answers